8-K: Profound Medical Announces Strong Preliminary Revenue Growth and Transition to U.S. GAAP Reporting

Profound Medical reports preliminary unaudited revenue growth of 105-110% year-over-year for the fourth quarter of 2024 and announces a transition to U.S. GAAP reporting.

Summary

• Profound Medical has announced preliminary unaudited revenues for the fourth quarter and full year of 2024.
• The company estimates fourth-quarter revenue to be between $4.1 million and $4.2 million, representing a year-over-year growth of 105% to 110%.
• Sequential quarter-over-quarter growth for Q4 is estimated to be between 45% and 48%.
• Full-year 2024 revenue is expected to be approximately $11.1 million to $11.2 million, compared to $7.2 million in the previous year.
• Profound will transition to reporting financial results in accordance with U.S. GAAP starting January 1, 2025.
• The company will also begin filing with the SEC using U.S. domestic forms.
• The company's presentation currency will remain the United States dollar.
• Profound is scheduled to present at the J.P. Morgan Healthcare Conference on January 16th, 2025.

Sentiment

Score: 8

Explanation: The document conveys a highly positive sentiment due to the strong revenue growth, successful reimbursement achievements, and the strategic move to U.S. GAAP reporting. The company's management also expresses confidence in future growth.

Positives

• The company experienced substantial revenue growth in the fourth quarter of 2024, with a year-over-year increase of 105% to 110%.
• Full-year 2024 revenue is significantly higher than the previous year, indicating strong overall growth.
• The transition to U.S. GAAP and SEC filings is expected to make it easier for U.S. investors to access and analyze the company's financial information.
• The TULSA procedure has achieved significant reimbursement milestones, which is expected to drive further adoption.
• The company has a strong balance sheet following a recent public offering of common shares.

Negatives

• The reported revenues are preliminary and unaudited, and actual results may differ.
• The company is in the early stages of exploring additional potential treatment markets for Sonalleve, which may take time to develop.

Risks

• The actual financial results may differ from the preliminary estimates due to various market factors and the company's ability to execute its plans.
• The company faces risks related to the medical device industry, regulatory approvals, reimbursement, economic factors, and competition.
• The success of the company's U.S. commercialization strategy for TULSA-PRO is not guaranteed.
• The company's ability to achieve its financial goals may be affected by market conditions and operational challenges.

Future Outlook

Profound believes it is on the cusp of entering a stage of escalating growth due to increased adoption of TULSA-PRO and favorable reimbursement conditions. The company plans to update investors as it progresses.

Management Comments

• Arun Menawat, Profound's CEO and Chairman, stated that the company was excited to see the adoption of TULSA-PRO increase.
• Dr. Menawat believes the company is on the cusp of entering a stage of escalating growth due to the strengthening of the balance sheet and favorable reimbursement for the TULSA procedure.
• Dr. Menawat also stated that the transition to U.S. GAAP and SEC filings will make it easier for investors to access and analyze the company's stock regulatory filings.

Industry Context

The announcement reflects a positive trend in the medical device industry, particularly in the area of minimally invasive procedures. The increased adoption of TULSA-PRO and favorable reimbursement conditions suggest a growing market for this type of technology. The transition to U.S. GAAP and SEC filings is a common step for companies seeking to attract U.S. investors.

Comparison to Industry Standards

• The reported revenue growth of 105-110% year-over-year for Q4 2024 is significantly higher than the average growth rate for medical device companies, which typically ranges from 5-15%.
• Companies like Intuitive Surgical (ISRG) and Medtronic (MDT), which are leaders in the medical device space, have shown consistent growth, but not at the same rate as Profound's reported Q4 growth.
• The transition to U.S. GAAP and SEC filings is a standard practice for companies listed on the NASDAQ, similar to other foreign private issuers like BioNTech (BNTX) and CureVac (CVAC).
• The reimbursement achievements for TULSA-PRO at Urology APC Level 7 are a significant milestone, as reimbursement is a key factor for the adoption of medical technologies. This is comparable to other medical device companies that have successfully navigated the reimbursement landscape.

Stakeholder Impact

• Shareholders are likely to react positively to the strong revenue growth and the transition to U.S. GAAP reporting.
• Employees may be motivated by the company's positive performance and future growth prospects.
• Customers (healthcare providers and patients) are expected to benefit from the increased availability and reimbursement of TULSA-PRO.
• Suppliers may see increased demand for their products and services due to the company's growth.

Next Steps

• Profound will present at the J.P. Morgan Healthcare Conference on January 16th, 2025.
• The company will continue to update investors on its progress.
• Profound will begin reporting financial results in accordance with U.S. GAAP and filing with the SEC using U.S. domestic forms.

Key Dates

Keywords

TULSA-PRO, revenue, medical device, U.S. GAAP, SEC, prostate cancer, Sonalleve, reimbursement, JPM 2025, financial results